Comparative Pharmacology
Head-to-head clinical analysis: GRIFULVIN V versus GRISEOFULVIN ULTRAMICROSIZE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRIFULVIN V versus GRISEOFULVIN ULTRAMICROSIZE.
GRIFULVIN V vs GRISEOFULVIN, ULTRAMICROSIZE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to microtubule-associated proteins and disrupts fungal mitotic spindle formation, thereby inhibiting fungal cell division. It also interferes with fungal nucleic acid synthesis.
Binds to tubulin, disrupting microtubule function and inhibiting fungal cell mitosis; deposited in keratin precursor cells, making keratin resistant to fungal invasion.
500 mg orally once daily (non-microsize formulation) or 250 mg twice daily; typical duration is 4-8 weeks for tinea capitis, 2-6 weeks for tinea corporis, 4-6 weeks for tinea pedis.
250-375 mg orally once daily or 500-750 mg orally once daily for severe infections.
None Documented
None Documented
Terminal half-life: 9–24 hours. Clinical context: Steady-state achieved in 2–5 days; prolonged in hepatic impairment.
9-24 hours (mean 15 hours); prolonged in liver disease.
Renal (1% unchanged), fecal (33% as metabolites), biliary (minor). Extensive hepatic metabolism; <1% excreted unchanged in urine.
Renal (<1% unchanged); fecal (36% as metabolites); tissue deposition may persist for weeks.
Category C
Category D/X
Antifungal
Antifungal